Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis

Annals of Neurology

Volumn 57, Issue 2, 2005, Pages 289-293

  Shiraishi, Hirokazu ^a   Motomura, Masakatsu ^a   Yoshimura, Toshiro ^b   Fukudome, Takayasu ^c   Fukuda, Taku ^a   Nakao, Yoko ^d   Tsujihata, Mitsuhiro ^d   Vincent, Angela ^e   Eguchi, Katsumi ^a,b  

^a Graduate School of Biomedical Sciences   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Nagasaki Kawatana Medical Center   (Japan)

^d Nagasaki Kita Hospital   (Japan)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MUSCLE BIOPSY; MYASTHENIA GRAVIS; NERVE ENDING; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; COMPLEMENT C3; FEMALE; HUMANS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MOTOR ENDPLATE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 13144277543     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20341     Document Type: Article

References (20)

1. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;1:116-119.
2. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99-106.
3. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
4. Scuderi F, Marino M, Colonna L, et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82:1139-1146.
5. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
6. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
7. Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004;62:2131-2132.
8. Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004;62:2132-2123.
9. Valenzuela DM, Stitt TN, DiStefano PS, et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995;15:573-584.
10. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 2002;25:4-16.
11. Tsujihata M, Yoshimura T, Satoh A, et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989;39:1359-1363.
12. Tsujihata M, Ito H, Satoh A, et al Semiquantitative measurement of acetylcholine receptor at the motor end-plate in myasthenia gravis. Intern Med 2001;40:376-381.
13. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977;52:267-280.
14. Engel AG, Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann NY Acad Sci 1971;183:46-63.
15. Drachman DB, Angus CW, Adams RN, et al. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298:1116-1122.
16. Tsujihata M, Satoh A, Yoshimura T, et al Effect of myasthenic immunoglobulin G on motor end-plate morphology. J Neurol 2003;250:75-82.
17. Lecky BR, Morgan-Hughes JA, Landon DN, Murray NM. Intercostal muscle acetylcholine receptors in longstanding ocular myasthenia. Lancet 1980;2:1311-1312.
18. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945-1950.
19. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584.
20. Kong XG, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interfance. EMBO Rep 2004;5:183-188.